increased tumor incidence_Msh2<tm1Rak>/Msh2<+>

http://metadb.riken.jp/0002020I129P2OlaHsdMsh2tm1RakMsh2Msh2tm1RakMsh2

increased tumor incidence_Msh2<tm1Rak>/Msh2<+>

表現型アノテーション

MGI marker

http://metadb.riken.jp/db/mgi_rdf/variant_of

• mutS homolog 2
  http://metadb.riken.jp/db/mgi_rdf/MGI:101816

遺伝子型

http://metadb.riken.jp/db/mgi_rdf/allele_composition

• Msh2<tm1Rak>/Msh2<+>

アレルシンボル

http://metadb.riken.jp/db/mgi_rdf/allele_symbol

• Msh2<tm1Rak>|Msh2<+>

遺伝的背景

http://metadb.riken.jp/db/mgi_rdf/genetic_background

• involves: 129P2/OlaHsd

MP annotation

http://metadb.riken.jp/db/bioresource_schema/brs_indicatesPhenotype

• increased tumor incidence
  http://purl.obolibrary.org/obo/MP_0002020

文献

http://purl.org/net/cito/citesAsAuthority

• R. Smits, et.al., Somatic Apc mutations are selected upon their capacity to inactivate the beta-catenin downregulating activity., Genes, chromosomes & cancer, 2000, 29
  http://rdf.ncbi.nlm.nih.gov/pubmed/10992298